Cor Vasa 2005, 46(7-8):315-318
Ezetimibe - a step forward in the treatment of dyslipidemia
- Oddělení funkčního vyšetřování, Fakultní nemocnice Brno-Bohunice, Brno, Česká republika
Ezetimibe is a highly effective selective cholesterol inhibitor reducing cholesterol by an approx. 54%. Ezetimibe alone at a dose of 10 mg/day reduces mean plasma LDL-cholesterol levels by 18-20% in hypercholesterolemic patients. A combination of ezetimibe with a statin results in an additive reduction in LDL-cholesterol by as much as 25% compared with a statin alone. Administration of ezetimibe 10 mg daily combined with a statin 10 mg daily resulted in a reduction in LDL-cholesterol comparable to that obtained with the highest dose of a statin, including 80 mg atorvastatin and simvastatin. Ezetimibe is well tolerated both in monotherapy and as combination therapy with statins. Combination therapy including ezetimibe and a statin is very well tolerated and does not increase the incidence of side effects.
Keywords: Ezetimibe; Statins; Combination therapy
Published: July 1, 2005 Show citation